Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
France
/
Pharmaceuticals & Biotech
/
Ipsen
IPN
Ipsen
US And EU Controls And Pipeline Risks Will Erode Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
20 Jun 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€105.00
1.2% overvalued
intrinsic discount
09 Aug
€106.30
Loading
1Y
3.1%
7D
3.0%
Author's Valuation
€105.0
1.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€105.0
1.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-50m
4b
2014
2017
2020
2023
2025
2026
2028
Revenue €4.0b
Earnings €552.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.56%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.98%
Calculation
€552.30m
Earnings '28
x
18.33x
PE Ratio '28
=
€10.12b
Market Cap '28
€10.12b
Market Cap '28
/
82.12m
No. shares '28
=
€123.28
Share Price '28
€123.28
Share Price '28
Discounted to 2025 @ 5.98% p.a.
=
€103.56
Fair Value '25